


## Introduction

Semaglutide injections treat obesity in adults

December 2022, FDA approved adolescents BMI at or above the 95th percentile for age and sex<sup>1</sup>

Under HIPAA guidelines, demographics for individuals under the age of 18 cannot be disclosed


PurpleLab® identified a way to impute SDOH information



## Methodology

PurpleLab's HealthNexus™ platform analyzed semaglutide prescriptions written & dispensed monthly from September 2022 to March 2024

Open and combined open/closed claims were used in the analysis



# Imputing SDOH Information on Pharmacy Claims

**Russell D. Robbins, MD, MBA**  
Chief Medical Information Officer

**Douglas Londono, PHD**  
VP, Advanced Analytics

**Grace Kane**  
Statistical Data Analyst

	Written	Dispensed
<b>Open Claims</b>		
Commercial	6482	2910
Medicaid	3558	1828
Other	1430	730
<b>Totals</b>	<b>11470</b>	<b>5481</b>
<b>Open &amp; Closed</b>		
Commercial	6802	3203
Medicaid	5706	3723
Other	1773	991
<b>Totals</b>	<b>14281</b>	<b>7917</b>

## Next Steps & Conclusions

Income data are not available for the adolescent population

Infer lower income in the Medicaid population


Monitor the use of weight loss drugs in the adolescent populations

Need to follow cohort as they change health plans

**Lower income is not a barrier to receiving the medication when clinically indicated**

**40%**  
Male

**60%**  
Female



## Findings

Due to HIPAA regulations, SDOH information can not be released on children under the age of 18

Children covered by parents in commercial plans

Children direct and indirect under Medicaid

Open claims show majority in commercial group

Medicaid is a closed claims system

Open & Closed shows more equal dispensing rates

1. <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022#new-uses>